Search
Carboplatin Treatment Options
A collection of 1669 research studies where Carboplatin is the interventional treatment. These studies are located in the United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
793 - 804 of 1669
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
Completed
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2022
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +241 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Completed
This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osm... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/11/2022
Locations: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota +1 locations
Conditions: Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma, Oligoastrocytoma
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
Withdrawn
The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal residual disease detected after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2022
Locations: Local Institution, Jacksonville, Florida +12 locations
Conditions: Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Withdrawn
Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
03/03/2022
Locations: Cancer Research Network of Nebraska / Oncology Associates, Omaha, Nebraska
Conditions: Non-small Cell Lung Cancer (NSCLC)
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
Terminated
In this multi-institution phase I/II trial, the investigators have chosen paclitaxel and carboplatin using a schedule and doses identical to those used in the CROSS trial. Following a run-in with nivolumab alone at 240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care established by the CROSS trial: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2022
Locations: University of Califonia, San Diego, La Jolla, California +4 locations
Conditions: Esophageal Squamous Cell Carcinoma
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
Completed
The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2022
Locations: Emory University, Atlanta, Georgia +3 locations
Conditions: Advanced Solid Neoplasm
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
Completed
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2022
Locations: Research Site 7814 - Compassionate Care Research Group, Fountain Valley, California +146 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Terminated
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and gemcitabine (GC therapy) for participants with metastatic triple negative breast cancer.
The study was an open-label and 102 participants were randomly assigned (1:1:1 fashion) to 1 of the 3 following treatment groups:
* Group 1: GC therapy (Days 1 and 8 of 21-day cycle... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2022
Locations: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona +53 locations
Conditions: Triple-Negative Breast Neoplasms, Breast Neoplasm, Breast Cancer, Triple-Negative Breast Cancer
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
Completed
This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC. This study will help to better define optimal preoperative regimens for patients with resectable NSCLC. Since both of these drugs are potent radio-sensitizers, the concurrent use with radiation therapy at these weekly doses may produce not only radio-sensitization, but also considerable antitumor efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2022
Locations: Tennessee Oncology, PLLC, Nashville, Tennessee
Conditions: Lung Cancer
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
Completed
The purpose of this study is to see if adding two targeted drugs (bevacizumab and erlotinib) further improves the response to chemotherapy (5-FU, paclitaxel, carboplatin) and radiation therapy in patients with operable esophageal cancer.
Side effects (toxicity) information will also be collected.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2022
Locations: Florida Cancer Specialists, Fort Myers, Florida +8 locations
Conditions: Esophageal Cancer
Pembro/Carbo/Taxol in Endometrial Cancer
Completed
This is a single-arm, open-label, multi-center phase II study for subjects with measurable advanced or recurrent endometrial cancer using pembrolizumab in combination with carboplatin and paclitaxel chemotherapy. As this combination of agents has not been tested in this subject population, the first six subjects enrolled will constitute a safety run-in cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/17/2022
Locations: Ironwood Cancer and Research Centers, Mesa, Arizona +5 locations
Conditions: Endometrial Cancer, Endometrial Adenocarcinoma
Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Completed
Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/16/2022
Locations: Rush University Medical Center, Chicago, Illinois +1 locations
Conditions: Head and Neck Cancer, Carcinoma, Squamous Cell, Neoplasms, Oral, Neoplasms, Pharyngeal
793 - 804 of 1669